France-based precision oncology diagnostics technology developer HalioDx closed a €18.5m ($22.3m) series B round yesterday featuring Sham Innovation Santé, a fund formed by health insurance provider Sham.
The round included healthcare investment holding company MI Care, Amundi Private Equity Funds and Quest for Growth as well as Sofipaca and BNP Paribas Development, respective subsidiaries of financial services firms Credit Agricole and BNP Paribas, and state-owned investment bank Bpifrance’s PSIM fund.
Founded in 2014, HalioDx is developing diagnostic tests for tumours…
